Hormonal therapy has been shown to be very effective in reducing the risk of hormone-receptor-positive, early-stage breast cancer coming back (recurring) in post-menopausal women. To reduce the risk of recurrence, hormonal therapy medicines usually are taken for 5 years after the main treatment is completed. Taking medicine after the main treatment is done is known as adjuvant therapy.
Aromatase inhibitors such as Arimidex (chemical name: anastrazole), Aromasin (chemical name: exemestane), and Femara (chemical name: letrozole) have been shown to be more effective than tamoxifen, an older hormonal therapy medicine.
In this study, Femara was shown to be more effective than tamoxifen in reducing the risk of breast cancer coming back. All the women in this study had early-stage breast cancer. Two groups of women got the most benefit from Femara:
The results of this study add to the growing body of evidence that aromatase inhibitors can help reduce the risk of breast cancer coming back in post-menopausal women with hormone-receptor-positive, early-stage breast cancer.
LONDON (Reuters) - New 4-year clinical trial results confirm the effectiveness of Novartis's drug Femara (letrozole) in cutting the risk of breast cancer returning, researchers said on Monday.
The latest 4-year figures from a study involving nearly 5,000 patients are consistent with a previous 2-year analysis, and doctors reported no increase in adverse events with long-term treatment.
Femara belongs to a relatively new class of drugs known as aromatase inhibitors, which are prescribed for postmenopausal women with hormone-sensitive tumours.
The drugs, which cut the risk of cancer recurrence by blocking the enzyme aromatase, are given following breast cancer surgery and are usually taken for 5 years.
Data presented at the European Society of Medical Oncology Congress in Istanbul showed that women on Femara had an 18-percent reduction in their overall risk of breast cancer recurrence after an average 51 months, compared with those taking the older hormonal therapy tamoxifen.
The use of Femara also resulted in greater disease-free survival in two groups of women particularly at risk of recurrence -- those whose cancer had already spread to the lymph nodes at the time of diagnosis and those who had received chemotherapy.
In these groups, the risk of recurrence was reduced in the study by 23 percent and 26 percent, respectively.
Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003
Learn more about our commitment to your privacy
© 2009 Breastcancer.org - All rights reserved.
Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.
